John V. Heymach
Lung cancer leader behind trials that changed treatment of EGFR-mutant and stage III disease.
John Heymach is a medical oncologist and cancer biologist and the principal investigator of AEGEAN (perioperative durvalumab) and a leader of EGFR and KRAS-directed programmes including work on osimertinib in stage III disease (LAURA) and targeting drug-tolerant persister cells.
| Title | Journal | Year |
|---|---|---|
| Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer | New England Journal of Medicine | 2023 |
| Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial | Lancet Oncology | 2010 |
Pages like this
not linked directly; found by shared links- TrialLAURA
Shares Osimertinib, EGFR, Non-small-cell lung cancer.
- PersonPasi A. Jänne
Shares Osimertinib, KRAS, EGFR, Non-small-cell lung cancer.
- PersonJean-Charles Soria
Shares Osimertinib, EGFR, Non-small-cell lung cancer.
- PersonHelena A. Yu
Shares Osimertinib, EGFR, Non-small-cell lung cancer.
- PersonYuichiro Ohe
Shares Osimertinib, Small-cell lung cancer, Non-small-cell lung cancer.
- CollectionLUNGevity Foundation (and GO2 for Lung Cancer)
Shares KRAS, Small-cell lung cancer, EGFR, Non-small-cell lung cancer.
- IdeaAdd the second drug on day one when the escape route is predictable
Shares Osimertinib, KRAS, EGFR, Non-small-cell lung cancer.
- PersonMyung-Ju Ahn
Shares Osimertinib, EGFR, Head and neck squamous cell carcinoma, Non-small-cell lung cancer.